• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Modus Therapeutics

0.37 SEK+3.06 %24.7. klo 18.25
Less than 1K followers

MODTX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.06 %
-1.86 %
-11.90 %
+17.09 %
+21.71 %
-24.92 %
-58.29 %
-81.81 %
-82.12 %

Modus Therapeutics operates in biotechnology. The product portfolio includes the drug candidate sevuparin. The company's focus is to develop sevuparin for patients with sepsis, septic shock and other conditions with systemic inflammation. In addition to its core business, it also offers service and related ancillary services. The business and related research are conducted with the largest presence in Sweden.

Read more
Market cap
55.02M SEK
Turnover
25.54K SEK
Revenue
EBIT %
P/E
Dividend yield-%
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
3rd party
ShowingAll content types

Financial calendar
26.8.
2026

Interim report Q2'26

24.11.
2026

Interim report Q3'26

24.2.
2027

Annual report '26

Regulatory press release18.06.2026 klo 19.10

Modus Therapeutics: SEVUSMART manuscript made available online ahead of peer review in Nature Communications

Modus Therapeutics
Press release16.06.2026 klo 12.15

Modus Therapeutics reports on preclinical data on sevuparin in CKD with anemia presented at EHA2026

Modus Therapeutics
Regulatory press release28.05.2026 klo 13.30

Annual General Meeting in Modus Therapeutics Holding AB (publ)

Modus Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release26.05.2026 klo 09.00

Modus Therapeutics publishes interim report for Q1 2026

Modus Therapeutics
Press release21.05.2026 klo 15.30

Modus Therapeutics to present sevuparin data at the European Iron Club Meeting 2026 in Dublin

Modus Therapeutics
Press release13.05.2026 klo 11.15

Modus Therapeutics to present preclinical data on sevuparin in CKD with anemia at EHA2026 in Stockholm

Modus Therapeutics
Regulatory press release27.04.2026 klo 23.15

Modus announces outcome of exercise of warrants of series TO 2026 and receives approximately SEK 9.5 million

Modus Therapeutics
Regulatory press release27.04.2026 klo 15.00

Notice to Annual General Meeting in Modus Therapeutics Holding

Modus Therapeutics
Regulatory press release15.04.2026 klo 09.00

Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2025

Modus Therapeutics
Regulatory press release14.04.2026 klo 17.00

KDventures AB subscribes for all of its warrants of series 2025/2026 in Modus Therapeutics

Modus Therapeutics
Regulatory press release13.04.2026 klo 14.45

Correction of Previously Communicated Press Release

Modus Therapeutics
Regulatory press release13.04.2026 klo 09.00

Today the Exercise Period Begins for Modus Therapeutics Warrants Series 2025/2026

Modus Therapeutics
Regulatory press release25.02.2026 klo 09.00

Modus Therapeutics publishes year-end report for 2025

Modus Therapeutics
Press release10.12.2025 klo 14.00

First Patient Dosed in Part 2 of Modus Therapeutics’ Phase IIa Study in Chronic Kidney Disease with Anemia

Modus Therapeutics
Press release10.12.2025 klo 11.57

DNB Carnegie Access: Modus Therapeutics Holding: Discontinuing coverage

Modus Therapeutics
Press release28.11.2025 klo 16.00

DNB Carnegie Access: Modus Therapeutics Holding: Funding for next step secured – Q3 review

Modus Therapeutics
Regulatory press release26.11.2025 klo 09.00

Modus Therapeutics publishes Interim report for the third quarter 2025

Modus Therapeutics
Press release03.11.2025 klo 14.00

Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia

Modus Therapeutics
Regulatory press release24.10.2025 klo 09.30

Change of Certified Adviser (CA) to Bergs Securities

Modus Therapeutics
Press release18.09.2025 klo 10.00

Modus Therapeutics data to be presented at the 32nd Symposium on Glycosaminoglycans – sevuparin in focus for CKD with anemia

Modus Therapeutics